

## Corporis Medical & LAPRIXA™

Corporis Medical is a young medical device company which started its operations in 2015, focusing on developing innovative solutions for improving access, closure and diagnostic measurements for minimally invasive interventional procedures. The company has several products in development in collaboration with a network of partners (KOL, designers, suppliers, distributors).

LAPRIXA™ is the first and the **smallest tissue blood pressure** measurement device in the world that, unlike others, corrects for general perfusion abnormalities (hyper- or hypotension), providing surgeons with an **immediate patient-customized, objective** reading about the viability of a tissue. The obtained information is crucial in critical decision-making during colorectal surgery, reducing the occurrence of anastomotic leakage.



The LAPRIXA™

### Urgent unmet need in GI surgery

Anastomotic leaks (AL), defined as “a leak of intestinal contents from a surgical join”, is the most feared post-operative complication after gastrointestinal (GI)-surgery. AL translates to re-operations, intensive care admissions, disability, diminished quality of life or even death, for many patients. Considering a **10% incidence rate**, with ~ 2 million yearly GI-surgeries performed in Europe and the US alone, more than 200.000 cases will suffer from an AL. The health care economic impact of this exceeds **€7,3 billion annually**, which on average represents a 3-4-fold increase when compared to surgeries without complications.

### LAPRIXA™ predicts ~90% Anastomotic Leakage

Based on a pilot first-in-man clinical trial performed with a first-generation LAPRIXA™ device, we obtained a positive predictive value of ~89% for the occurrence of AL postoperatively.

### Entering clinical validation stage

Next steps in the development involve clinical validation and proof of clinical claims by safety, efficacy and randomized multi-center clinical trials.

To prepare, support and execute the clinical trials we are establishing a solid consortium, consisting of **key reference centers and opinion leaders in GI-surgery** in The Netherlands including NKI-AVL (prof. Dr. G. Beets), Amsterdam UMC (prof. Dr. D.I. van der Peet) and MUMC+ (prof. Dr. N. Bouvy). Expansion of this consortium is foreseen.

We are confident that the LAPRIXA™ device will revolutionize the clinical pathway of patients undergoing GI-surgeries by reducing AL significantly and therefore greatly reducing healthcare costs and improving patients’ quality of life.

For more information about LAPRIXA™, please contact our program manager Josien Landman.

#### Anastomotic leakage impact in numbers (EU&US)

**Total number of GI surgeries annually** ~2 000 000

**AL incidence rate** 9-16%\*  
(\*dependent on anatomic site and country)

**AL mortality rate** 6-37%\*  
(\*dependent on anatomic site and country)

**Average number of AL cases annually** ~200 000

**Total health care costs of AL complications** ~€7,3 billion

#### Multicenter randomized clinical trial

**Centers involved** MUMC+, NKI-AVL, Amsterdam UMC, Zuyderland MC, Zaan MC and Spaarne Gasthuis

**Number of subjects** 710

**Start date/end date** 07/2024 – 07/2025

#### Contact Details

**Corporis Medical** Josien Landman, Program Mgr.  
**Oxfordlaan 55** T: +31 6 18527590  
**6229 EV Maastricht** E: [josien.landman@corporis-medical.com](mailto:josien.landman@corporis-medical.com)  
**The Netherlands**